FY2026 EPS Estimates for AstraZeneca Increased by Analyst

AstraZeneca PLC (NASDAQ:AZN) – Investment analysts at Zacks Research boosted their FY2026 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Tuesday, December 30th. Zacks Research analyst Team now expects that the company will post earnings of $5.06 per share for the year, up from their prior estimate of $5.05. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca’s Q2 2027 earnings at $1.41 EPS, Q3 2027 earnings at $1.52 EPS and FY2027 earnings at $5.83 EPS.

Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Cowen reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Trading Down 0.6%

AZN opened at $91.93 on Thursday. AstraZeneca has a 52 week low of $61.24 and a 52 week high of $94.01. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $89.04 and a 200-day simple moving average of $80.96. The firm has a market cap of $285.12 billion, a P/E ratio of 30.54, a P/E/G ratio of 1.71 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.05. The firm had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AZN. Voya Investment Management LLC increased its stake in AstraZeneca by 68.2% in the third quarter. Voya Investment Management LLC now owns 1,899,502 shares of the company’s stock valued at $145,730,000 after purchasing an additional 770,417 shares during the last quarter. SCS Capital Management LLC acquired a new stake in AstraZeneca in the 1st quarter worth about $3,066,000. Robbins Farley acquired a new stake in AstraZeneca in the 2nd quarter worth about $1,857,000. Oliver Luxxe Assets LLC grew its holdings in AstraZeneca by 6.0% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after buying an additional 4,449 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of AstraZeneca by 15.2% during the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after acquiring an additional 1,605,133 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.